Financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with Simufilam in Alzheimers disease. Here are some of the key things you need to know about the coronavirus pandemic.
Source: streetinsider.comPublished on 2022-08-03
Related news
- ClassLink and Canva for Education Partner to Deliver Creativity to Classrooms
- Monitoring city mobility from the skies
- iTWire - New Hasura GraphQL APIs for Snowflake streamline embedded analytics and accelerate data access
- Asceneuron Awarded Second Grant from The Michael J . Fox Foundation for Accelerated Research into Novel Parkinson Disease Therapies
- Delayed by COVID , CT redistricting ramps up | Hartford Business Journal
- The City of Baltimore is launching an updated open data portal on December 31
- Google Greenwashes a Dirty Partnership with Saudi Aramco
- Four ways the finance sector can end financial exclusion in 2021
- An Overview Of Today Alzheimer Disease Development Field
- Acceldata announces USD 50 Million in Series C Funding to expand market leadership and product innovation in Data Observability
- RARE - X Launches Diversity , Equality , and Inclusion Program
- Saudi Arabia Tourism Landscape Establishing a Vision | By Zabada N . Abouelhana and Ahmad Yousry Elbeheiry
- Airbus forecasts $4 . 6 trillion global market for aircraft services in next 20 years
- Researchers study COVID - 19 and its impact on crime in Vancouver , Canada
- Let Stop Calling Taiwan a Digital Democracy ( And Start Telling Better Digital Stories )